Amber Vania, DO
Family Medicine · Boise, IDNPI 1922311042
Payments from drug & device makers
Across 99 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$243
- Exact Sciences$243
- AstraZeneca$207
- Novo Nordisk$180
- Amgen$133
- Lilly USA, LLC$125
- plus $643 from 18 others
What the payments were for
- Food & beverage$1,76099%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $243 |
| Exact Sciences | 2 | $243 |
| AstraZeneca | 11 | $207 |
| Novo Nordisk | 14 | $180 |
| Amgen | 7 | $133 |
| Lilly USA, LLC | 9 | $125 |
| Boehringer Ingelheim | 6 | $113 |
| Pfizer | 6 | $87 |
| Johnson & Johnson | 5 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $48 |
| Mylan Specialty L.p. | 2 | $43 |
| Novartis | 2 | $36 |
| Medtronic | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Astellas Pharma US Inc | 2 | $24 |
| Exeltis, USA Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Sonex Health, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,775 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $61,819 |
| MounjaroTirzepatide | 50 | $52,715 |
| JardianceEmpagliflozin | 35 | $49,849 |
| EliquisApixaban | 34 | $37,641 |
| TrulicityDulaglutide | 28 | $36,068 |
| RybelsusSemaglutide | 17 | $28,639 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,582 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $20,864 |
| XareltoRivaroxaban | 13 | $20,234 |
| FarxigaDapagliflozin Propanediol | 11 | $19,066 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $15,642 |
| Repatha SureclickEvolocumab | 13 | $11,644 |
| MyrbetriqMirabegron | 13 | $10,303 |
| Aripiprazole | 20 | $6,090 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $180 | $90,45882 claims |
| Lilly USA, LLCMounjaro, Trulicity | $125 | $88,78378 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $12 | $52,59878 claims |
| Boehringer IngelheimJardiance | $113 | $49,84935 claims |
| PfizerEliquis | $87 | $37,64134 claims |
| AstraZenecaFarxiga, Crestor | $207 | $22,25823 claims |
| Johnson & JohnsonXarelto | $65 | $20,23413 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $15,64218 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $10,30313 claims |
| AbbVieSynthroid | $243 | $3,09037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Boise
- Brock McConneheyBoise$4.5M
- Diane McConneheyBoise$681K
- Phyllis YouBoise$88K
- John EckBoise$55K
- Kara CadwalladerBoise$24K
- Cyrus VaniaBoise$9K
- Joshua AdamsBoise$8K
- Nicole StiversBoise$7K
- Ammon RobertsBoise$7K
- Mark TurnerMeridian$40.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.